Vertex Pharmaceuticals NASDAQ: VRTX is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the pain management sector, presenting a compelling growth opportunity for the company and its investors. As the global market seeks effective, non-opioid pain treatments, Vertex's advancements in this area could solidify its leadership in developing next-generation pain solutions, substantially increasing its market va ...

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much.However, there are exceptions. Sometimes, a stock has a potential catalyst right around the corner. In such a case, investors could be much better off buying sooner rather than later.Vertex Pharmaceuticals (VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30?A key date for VertexWhat's ...

On Sunday, Vertex Pharmaceuticals Incorporated VRTX announced multiple program updates, including:In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates across major markets ...

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, was recognized on Built In's 50 Best Remote Large Places to Work and 100 Best Remote Places to Work lists. This annual awards program recognizes companies of all sizes, from startups to enterprises, celebrating remote-first employers and those in large tech markets across the U.S. "What an incredible honor to be recognized by Built In – this award val ...

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on Built In’s 50 Best Remote Large Places to Work and 100 Best Remote Places to Work lists. This annual awards program recognizes companies of all sizes, from startups to enterprises, celebrating remote-first employers and those in large tech markets across the U.S. “What an incredible honor to be recognized by Built In – this award val ...

Vertex (VERX) shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8%, respectively. This strong performance highlights investor confidence in Vertex's innovative tax compliance solutions, strategic partnerships and expanding client base.Here's why adding Vertex to your portfolio makes sense now.Factors That May Benefit VertexThe increasing adoption of e-invoicing globally an ...

Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. Here's why.This growth prospect just took a heavy hitVertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the v ...

Vertex Pharmaceuticals (VRTX) announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed under the brand name Alyftrek.Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator (CFTR) gene responsive to the drug. The ...

Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.Analyst Salveen Richter maintained a Buy rating for Vertex Pharmaceuticals and price target of $602.The Vertex Pharmaceuticals Thesis: During the initial launch of Alyft ...

Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.But in recent weeks, Vertex stock has declined, and last week it lost nearly 12% in one trad ...